Company Filing History:
1 out of 1 
1 out of 832,812 Years Active: 2001
Title: Elizabeth Baker: Innovator in Fragile X Syndrome Research
Introduction
Elizabeth Baker is a prominent inventor based in Glenelg North, Australia. With a total of two patents to her name, she has significantly contributed to the understanding and potential treatment of fragile X syndrome, a genetic condition often associated with mental retardation.
Latest Patents
Baker's latest patents focus on monoclonal and polyclonal antibodies relating to fragile X syndrome. Specifically, she has obtained the DNA sequence spanning the fragile X site on the X human chromosome in a purified and isolated form. This achievement is significant as it permits the diagnosis and treatment of mental disorders linked to fragile X syndrome. Furthermore, her patents disclose monoclonal and polyclonal antibodies to an amino acid sequence encoded by SEQ ID NO:1, a DNA sequence from the fragile X site, further enhancing the potential for clinical applications.
Career Highlights
Throughout her career, Elizabeth Baker has worked with esteemed institutions, including the Adelaide Medical Centre for Women and Children. Her work there has laid the groundwork for advancements in genetic research and therapeutic development.
Collaborations
Baker has collaborated with notable colleagues in her field, including Grant R. Sutherland and Robert I. Richards. Their joint efforts have helped propel research initiatives and foster innovations in the understanding of genetic disorders.
Conclusion
Elizabeth Baker stands as a notable figure in the field of biomedical research, particularly in relation to fragile X syndrome. Her patents and collaborative efforts demonstrate her commitment to improving diagnostic and therapeutic approaches to genetic disorders, marking her as an influential inventor in her domain.